Stockreport

This Is Why Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) CEO Compensation Looks Appropriate [Yahoo! Finance]

Praxis Precision Medicines, Inc.  (PRAX) 
PDF The total compensation is 50% less than the average for the industry Praxis Precision Medicines' three-year loss to shareholders was 84% while its EPS grew by 30% ove [Read more]